** Shares of Argent BioPharma RGT.AX rise as much as 52.9% to A$0.260, their biggest intraday pct gain since Oct 1, 2024
** The clinical-stage biopharma co completes $4.5 mln capital raise at $0.40 per share
** Issue price represents a premium of 276.5%, compared with stock's last closing price of A$0.17
** Says placement will help advance co's drug development pipeline, with focus on clinical studies for CannEpil - a seizure-control treatment for refractory epilepsy and cerebral palsy
** Stock hits its highest level since Dec 2
** About 231,485 shares change hands, 13.2 times the 30-day average volume of 17,562
** Stock fell 64.2% in 2024
(Reporting by Manasi Dasa Sundeep in Bengaluru)
((Manasi.DasaSundeep@ThomsonReuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.